




Florbetaben F 18

Revised: August 17, 2020.

CASRN: 902143-01-5



Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of florbetaben F 18 as a diagnostic agent. No information is available on the use of florbetaben F 18 during breastfeeding. The manufacturer recommends withholding breastfeeding for 24 hours after a diagnostic dose. Twenty-four hours is about 10 half-lives of fluoride F 18 and less than 0.01% of the radioactivity administered will remain in the body. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[1,2]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[3]

Drug Levels

F18 is a positron emitter with a principal decay energy of 0.6335 MeV, annihilation photons of 0.511 MeV, and a physical half-life of 1.8 hours and 0.07% of an administered dose appears in breastmilk.[4]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: Data, quantitative analysis and recommendations. *Nucl Med Commun.* 1989;10:15–27. PubMed PMID: 2645546.
2. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St Louis Mosby-Year Book, Inc 1995:1380-1.
3. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. *J Nucl Med.* 2000;41:863–73. PubMed PMID: 10809203.
4. Leide-Svegborn S, Ahlgren L, Johansson L, et al. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. *Eur J Nucl Med Mol Imaging.* 2016;43:808–21. PubMed PMID: 26732471.

Substance Identification

Substance Name

Florbetaben F 18

CAS Registry Number

902143-01-5

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Fluoride Radioisotopes

Diagnostic Agents